Moreover, IL2-tethered small EVs (IL2-sEVs) derived from engineered Jurkat T cells enhanced CD8+ T cell anticancer activity and reduced PD-L1 expression in melanoma cells via specific microRNAs, demonstrating their potential as cancer immunotherapeutic agents [143]. This evidence concerns the gene CD8A and cancer.